NASDAQ:QNRX

Quoin Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy QNRX

*Your capital is at risk

$4.43

-0.130 (-2.85%)

At Close: Jun 03, 2026

Quoin Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 13.39M and sold 0 QNRX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	13.39M shares
● Sell	0 shares
100% Buy Activity Moderate Positive Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Dec 23, 2024 Buy	Series G Warrants (right to buy) P-Purchase	Culverwell Anthony James Director	Director	100 000 Value: $45.0K
Dec 09, 2024 Buy	Share Option (Right to Buy) A-Award	Cooper Joseph Patrick Director	Director	50 714 Value: $39.6K
Dec 09, 2024 Buy	Share Option (Right to Buy) A-Award	Dunn Gordon Chief Financial Officer	C-Suite Officer	338 994 Value: $264.4K
Dec 09, 2024 Buy	Share Option (Right to Buy) A-Award	Culverwell Anthony James Director	Director	50 714 Value: $39.6K
Dec 09, 2024 Buy	Share Option (Right to Buy) A-Award	Carter Denise P. Chief Operating Officer	C-Suite Officer	536 609 Value: $418.6K
Dec 09, 2024 Buy	Share Option (Right to Buy) A-Award	Sember Michael T Director	Director	50 714 Value: $39.6K
Dec 09, 2024 Buy	Share Option (Right to Buy) A-Award	Myers Michael Chief Executive Officer	CEO / President	536 603 Value: $418.6K
Dec 09, 2024 Buy	Share Option (Right to Buy) A-Award	Leong Natalie Ee Mun Director	Director	50 714 Value: $39.6K
Dec 09, 2024 Buy	Share Option (Right to Buy) A-Award	Langer Dennis Director	Director	50 714 Value: $39.6K
Dec 09, 2024 Buy	Share Option (Right to Buy) A-Award	Cooper Joseph Patrick Director	Director	50 714 Value: $39.6K
Dec 09, 2024 Buy	Share Option (Right to Buy) A-Award	Dunn Gordon Chief Financial Officer	C-Suite Officer	338 994 Value: $264.4K
Dec 09, 2024 Buy	Share Option (Right to Buy) A-Award	Culverwell Anthony James Director	Director	50 714 Value: $39.6K
Dec 09, 2024 Buy	Share Option (Right to Buy) A-Award	Carter Denise P. Chief Operating Officer	C-Suite Officer	536 609 Value: $418.6K
Dec 09, 2024 Buy	Share Option (Right to Buy) A-Award	Sember Michael T Director	Director	50 714 Value: $39.6K
Dec 09, 2024 Buy	Share Option (Right to Buy) A-Award	Myers Michael Chief Executive Officer	CEO / President	536 603 Value: $418.6K
Dec 09, 2024 Buy	Share Option (Right to Buy) A-Award	Leong Natalie Ee Mun Director	Director	50 714 Value: $39.6K
Dec 09, 2024 Buy	Share Option (Right to Buy) A-Award	Langer Dennis Director	Director	50 714 Value: $39.6K
Sep 10, 2024 Buy	Ordinary Shares P-Purchase	Dunn Gordon Chief Financial Officer	C-Suite Officer	10 000 Value: $7K
Sep 10, 2024 Buy	Ordinary Shares P-Purchase	Dunn Gordon Chief Financial Officer	C-Suite Officer	10 000 Value: $9K
Sep 10, 2024 Buy	Ordinary Shares P-Purchase	Dunn Gordon Chief Financial Officer	C-Suite Officer	10 000 Value: $7K
Sep 10, 2024 Buy	Ordinary Shares P-Purchase	Dunn Gordon Chief Financial Officer	C-Suite Officer	10 000 Value: $9K
Sep 09, 2024 Buy	Ordinary Shares P-Purchase	Dunn Gordon Chief Financial Officer	C-Suite Officer	4 000 Value: $3K
Sep 09, 2024 Buy	Ordinary Shares P-Purchase	Dunn Gordon Chief Financial Officer	C-Suite Officer	4 000 Value: $3K
Sep 09, 2024 Buy	Ordinary Shares P-Purchase	Dunn Gordon Chief Financial Officer	C-Suite Officer	856 Value: $685
Sep 09, 2024 Buy	Ordinary Shares P-Purchase	Dunn Gordon Chief Financial Officer	C-Suite Officer	4 000 Value: $3K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT QUOIN PHARMACEUTICALS, LTD.

Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia....

Read Full Profile Here